If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Strattera Summary of Product Characteristics (SmPC)
Strattera (atomoxetine) should not be used in some patients
to the active substance or to any of the excipients listed in section
should not be used in combination with monoamine oxidase inhibitors
(MAOI). Atomoxetine should not be used within a minimum of 2 weeks
after discontinuing therapy with MAOI. Treatment with MAOI should not
be initiated within 2 weeks after discontinuing atomoxetine.
Atomoxetine should not be used in patients with narrow-angle
glaucoma, as in clinical trials the use of atomoxetine was associated
with an increased incidence of mydriasis.
should not be used in patients with severe cardiovascular or
cardiovascular disorders may include severe hypertension, heart
failure, arterial occlusive disease, angina, haemodynamically
significant congenital heart disease, cardiomyopathies, myocardial
infarction, potentially life-threatening arrhythmias and
channelopathies (disorders caused by the dysfunction of ion
channels). Severe cerebrovascular disorders may include cerebral
aneurysm or stroke.
should not be used in patients with pheochromocytoma or a history of
Summary of Product Characteristics
Date of Last Review:November 02, 2018
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org